PE20071020A1 - Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa - Google Patents

Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa

Info

Publication number
PE20071020A1
PE20071020A1 PE2007000237A PE2007000237A PE20071020A1 PE 20071020 A1 PE20071020 A1 PE 20071020A1 PE 2007000237 A PE2007000237 A PE 2007000237A PE 2007000237 A PE2007000237 A PE 2007000237A PE 20071020 A1 PE20071020 A1 PE 20071020A1
Authority
PE
Peru
Prior art keywords
glycine
derivative compounds
naphthyridin
dihydro
oxo
Prior art date
Application number
PE2007000237A
Other languages
English (en)
Inventor
Duke M Fitch
Mariela Colon
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20071020A1 publication Critical patent/PE20071020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE GLICINA N-SUSTITUIDOS DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C10), ALQUENILO(C2-C10), CICLOALQUILO(C3-C8), ENTRE OTROS; R2 ES NR6R7 U OR8, DONDE R6 Y R7 SON CADA UNO H, ALQUILO(C1-C10), ALQUENILO(C2-C10), HETEROCICLOALQUILO(C3-C8), ENTRE OTROS; R8 ES H, UN CATION O ALQUILO(C1-C10) OPCIONALMENTE SUSTITUIDO CON CICLOALQUILO(C3-C8), HETEROCICLOALQUILO(C3-C8), ARILO(C6-C14) O HETEROARILO; X, Y, W Y Z SON CADA UNO CR9 O N, DONDE R9 ES H, NITRO, CN, HALOGENO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{[1-(2-CICLOPROPILETIL)-4-HIDROXI-2-OXO-1,2-DIHIDRO-1,8-NAFTIRIDIN-3-IL]CARBONIL}GLICINA, N-{[4-HIDROXI-1-(3-METILBUTIL)-2-OXO-1,2-DIHIDRO-1,8-NAFTIRIDIN-3-IL]CARBONIL}GLICINA, N-{[1-(3,3-DIMETILBUTIL)-4-HIDROXI-2-OXO-1,2-DIHIDRO-1,8-NAFTIRIDIN-3-IL]CARBONIL}GLICINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DE PROLIL HIDROXILASAS QUE REGULAN EL FACTOR INDUCIBLE POR HIPOXIA (HIF) SIENDO UTILES EN EL TRATAMIENTO DE ANEMIA
PE2007000237A 2006-03-07 2007-03-05 Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa PE20071020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77973706P 2006-03-07 2006-03-07

Publications (1)

Publication Number Publication Date
PE20071020A1 true PE20071020A1 (es) 2007-12-11

Family

ID=38475787

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000237A PE20071020A1 (es) 2006-03-07 2007-03-05 Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa

Country Status (7)

Country Link
US (2) US7897612B2 (es)
EP (1) EP1991227A2 (es)
JP (1) JP2009529536A (es)
AR (1) AR059733A1 (es)
PE (1) PE20071020A1 (es)
TW (1) TW200808793A (es)
WO (1) WO2007103905A2 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229647B1 (ko) * 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
LT3357911T (lt) 2006-06-26 2022-08-10 Akebia Therapeutics Inc. Prolilo hidroksilazės inhibitoriai ir naudojimo būdai
AU2007334321B2 (en) * 2006-12-18 2012-03-08 Amgen Inc. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
AU2007334323B2 (en) 2006-12-18 2011-03-10 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
WO2008130527A1 (en) * 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
ES2442847T3 (es) * 2007-04-18 2014-02-13 Amgen, Inc Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa
US7569726B2 (en) 2007-04-18 2009-08-04 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
EP2150251B9 (en) 2007-05-04 2013-02-27 Amgen, Inc Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (en) * 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones that inhibit prolyl hydroxylase activity
US8962530B2 (en) * 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
WO2009039322A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) * 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009049112A1 (en) * 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
JP2011508725A (ja) * 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
CN101932324A (zh) * 2007-11-30 2010-12-29 葛兰素史密斯克莱有限责任公司 脯氨酰羟化酶抑制剂
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
WO2009086044A1 (en) * 2007-12-19 2009-07-09 Smith Kline Beecham Corporation Prolyl hydroxylase inhibitors
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
WO2009100250A1 (en) * 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
EP2257170B1 (en) * 2008-02-25 2012-12-26 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
EP2257171B1 (en) * 2008-02-25 2016-02-10 Merck Sharp & Dohme Corp. Tetrahydro-1h-pyrrolo-fused pyridones
WO2009134754A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazole glycinamides as prolyl hydroxylase inhibitors
JP2011519858A (ja) * 2008-04-30 2011-07-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラ−ゼ阻害剤
GB0809262D0 (en) * 2008-05-21 2008-06-25 Isis Innovation Assay
CN102264740B (zh) 2008-08-20 2014-10-15 菲布罗根有限公司 一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
JP2012500850A (ja) * 2008-08-25 2012-01-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
WO2010056767A1 (en) * 2008-11-14 2010-05-20 Fibrogen, Inc. Thiochromene derivatives as hip hydroxylase inhibitors
WO2010059552A1 (en) * 2008-11-18 2010-05-27 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
CA2748411A1 (fr) 2008-12-29 2010-07-08 Sanofi Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique comme activateurs de hif
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
SI2382215T1 (sl) * 2008-12-29 2020-06-30 Sanofi Derivati 2-piridin-2-il-pirazol-3(2H)-ona, njihova priprava in njihova terapevtska uporaba
ES2548250T3 (es) 2009-02-10 2015-10-15 Janssen Pharmaceutica, N.V. Quinazolinonas como inhibidores de prolilhidroxilasa
ES2702524T3 (es) * 2009-07-15 2019-03-01 Beijing Betta Pharmaceuticals Co Ltd Compuestos como miméticos de hipoxia, y composiciones, y usos de estos
AU2010271732B2 (en) * 2009-07-17 2016-08-25 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
AU2010314976B2 (en) 2009-11-06 2014-03-06 Aerpio Therapeutics Inc. Prolyl hydroxylase inhibitors
EP2603502B1 (en) 2010-08-13 2014-07-30 Janssen Pharmaceutica, N.V. 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
JP5952829B2 (ja) 2010-12-23 2016-07-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類
CN103608346B (zh) * 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
AU2012268400C1 (en) 2011-06-06 2016-12-22 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (es) 2011-06-06 2018-03-17
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
BR112014009910B1 (pt) 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. sal di-hidrato de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico, composição farmacêuticae pomada tópica
ES2718495T3 (es) 2012-12-21 2019-07-02 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
US9394300B2 (en) 2012-12-24 2016-07-19 Cadila Healthcare Limited Quinolone derivatives
CA3151685A1 (en) 2013-06-13 2014-12-18 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US20150164991A1 (en) * 2013-11-01 2015-06-18 Vanderbilt University Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
ES2862648T3 (es) 2014-06-25 2021-10-07 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
ES2898476T3 (es) 2014-09-02 2022-03-07 Sunshine Lake Pharma Co Ltd Compuesto de quinolona y uso del mismo
WO2016045127A1 (en) 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibitors of hif prolyl hydroxylase
WO2016118858A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146491B (zh) * 2015-03-27 2017-12-12 沈阳三生制药有限责任公司 被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
SI3277270T1 (sl) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Sestavki in postopki za zdravljenje anemije
EP3370518B1 (en) 2015-10-14 2023-08-23 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
CA3097219A1 (en) 2018-05-09 2019-11-14 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
CN110878096A (zh) * 2018-09-05 2020-03-13 石药集团中奇制药技术（石家庄）有限公司 一种1,7-萘啶类衍生物及其制备方法和用途
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN115835909A (zh) 2020-05-05 2023-03-21 泰昂治疗公司 ***素受体2型（cb2）调节剂和其用途
EP4342885A1 (en) 2022-09-20 2024-03-27 Basf Se N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides
WO2024061665A1 (en) 2022-09-20 2024-03-28 Basf Se N-(3-(aminomethyl)-phenyl)-5-(4-phenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-amine derivatives and similar compounds as pesticides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1644336T3 (da) * 2003-06-06 2011-05-09 Fibrogen Inc Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
MXPA06009132A (es) * 2004-02-11 2007-03-26 Smithkline Beecham Corp Inhibidores de integrasa de vih.

Also Published As

Publication number Publication date
EP1991227A2 (en) 2008-11-19
US20070213335A1 (en) 2007-09-13
WO2007103905A2 (en) 2007-09-13
AR059733A1 (es) 2008-04-23
WO2007103905A3 (en) 2008-10-30
JP2009529536A (ja) 2009-08-20
TW200808793A (en) 2008-02-16
US20090082357A1 (en) 2009-03-26
US7897612B2 (en) 2011-03-01

Similar Documents

Publication Publication Date Title
PE20071020A1 (es) Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
AR054272A1 (es) Derivados de 3- aminopirrilidinas tri, tetra - sustituidos
PE20090048A1 (es) Derivados de glicina n-sustituidos: inhibidores de prolil hidroxilasa
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
PE20080209A1 (es) Derivados de glicina como inhibidores de prolil hidroxilasa
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR066562A1 (es) Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
PE20130376A1 (es) [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
CO6220882A2 (es) Derivados de pirido-pirazina utiles como compuestos herbiicidas
PE20110671A1 (es) Derivados de diazabicicloalcanos como moduladores de la actividad de los receptores nicotinicos de la acetilcolina
AR081139A1 (es) Uracilos herbicidas
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
AR086589A1 (es) Compuestos imidazopiridina
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
AR056987A1 (es) Derivados de acetileno
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal